score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable		Clinical evidence		Copy Number	CRKL	Amplification				0.0	0.0									Putatively Actionable	Gefitinib	EGFR inhibition	Targeted therapy	CRKL amplification was observed in an EGFR inhibitor resistant tumor after researchers observed that cells from gefitinib-sensitive cell line (HCC827) overexpressing CRKL became resistant to gefitinib relative to controls.	Cheung HW, Du J, Boehm JS, et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011;1(7):608-25.	https://doi.org/10.1158/2159-8290.CD-11-0046						0				CRKL Amplification		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V197A	0.0976	41.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.V197A (Missense)	1.0	MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.E193K	0.0714	42.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.E193K (Missense)	1.0	MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.P345L	0.0909	33.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf													0				PDGFRA p.P345L (Missense)	0.0	MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.A18T	0.0543	92.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0.0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18	0				KRAS p.A18T (Missense)	1.0	MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat132		
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Splice Site	p.Y27N	0.1071	56.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0				PTEN p.Y27N (Splice Site)	1.0	MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.G667R	0.0962	52.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981													0				FBXW7 p.G667R (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E1220K	0.0847	59.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007													0				ATM p.E1220K (Missense)	1.0	MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.P1566L	0.0811	74.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007													0				ATM p.P1566L (Missense)	1.0	MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.V1629M	0.0476	84.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007													0				ATM p.V1629M (Missense)	1.0	MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.D2841N	0.0565	124.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007													0				ATM p.D2841N (Missense)	1.0	MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability			Guideline	Somatic Variant	STAG2	Splice Site	p.E16K	0.2	60.0	0.0	0.0																Investigate Actionability	0.0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				STAG2 p.E16K (Splice Site)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.W315*	0.1905	84.0	0.0	0.0																Investigate Actionability	0.0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				STAG2 p.W315* (Nonsense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Splice Site		0.1667	90.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				EZH2  (Splice Site)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.L297F	0.0727	55.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				RAD51C p.L297F (Missense)	1.0	MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.A1030V	0.0656	61.0	8e-06	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				BRIP1 p.A1030V (Missense)	1.0	MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.A776T	0.1071	56.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				BRIP1 p.A776T (Missense)	1.0	MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.A883V	0.066	106.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf													0				TSC1 p.A883V (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.V1056I	0.2381	42.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf													0				TET2 p.V1056I (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.G1218S	0.1077	65.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0				BRCA2 p.G1218S (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S3291F	0.127	63.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0				BRCA2 p.S3291F (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.T1219I	0.1132	53.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH6 p.T1219I (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.E307K	0.1183	93.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	Peng W, Chen JQ, Liu C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6(2):202-16.	https://doi.org/10.1158/2159-8290.CD-15-0283	Investigate Actionability	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0				PTEN p.E307K (Missense)	1.0	MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Splice Site	p.K727K	0.1064	47.0	0.0	0.0																Investigate Actionability	0.0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				PRPF8 p.K727K (Splice Site)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.E528K	0.1125	80.0	0.0	0.0																Investigate Actionability	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				ASXL1 p.E528K (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.D198N	0.1429	126.0	0.0	0.0																Investigate Actionability	0.0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				STAG2 p.D198N (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.R252L	0.1	50.0	0.0	0.0																Investigate Actionability	0.0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				STAG2 p.R252L (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.A867T	0.1148	61.0	0.0	0.0																Investigate Actionability	0.0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				STAG2 p.A867T (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.G891E	0.0496	121.0	0.0	0.0																Investigate Actionability	0.0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060	0				BLM p.G891E (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Biologically Relevant				Somatic Variant	MTOR	Missense	p.E883K	0.1319	91.0	0.0	0.0																					0				MTOR p.E883K (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Biologically Relevant				Somatic Variant	PMS2	Missense	p.V32I	0.1215	214.0	0.0	0.0																					0				PMS2 p.V32I (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Biologically Relevant				Somatic Variant	POT1	Missense	p.T41I	0.0761	92.0	0.0	0.0																					0				POT1 p.T41I (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Biologically Relevant				Somatic Variant	PAK1	Missense	p.G32E	0.1385	65.0	0.0	0.0																					0				PAK1 p.G32E (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Biologically Relevant				Somatic Variant	MDM2	Missense	p.G428D	0.1127	71.0	0.0	0.0																					0				MDM2 p.G428D (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Biologically Relevant				Somatic Variant	NF1	Missense	p.A656T	0.0515	97.0	0.0	0.0																					0				NF1 p.A656T (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.D1237N	0.0923	130.0	0.0	0.0																					0				NF1 p.D1237N (Splice Site)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Biologically Relevant				Somatic Variant	NF1	Missense	p.V1578I	0.0694	72.0	0.0	0.0																					0				NF1 p.V1578I (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Biologically Relevant				Somatic Variant	TPX2	Missense	p.P422S	0.0825	97.0	0.0	0.0																					0				TPX2 p.P422S (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Biologically Relevant				Somatic Variant	TPX2	Missense	p.P427S	0.0745	94.0	0.0	0.0																					0				TPX2 p.P427S (Missense)		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	MEL-IPI_Pat132-Normal-SM-5VWHR
Biologically Relevant				Copy Number	FANCL	Amplification				0.0	0.0																					0				FANCL Amplification		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	
Biologically Relevant				Copy Number	MAPK1	Amplification				0.0	0.0																					0				MAPK1 Amplification		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	
Biologically Relevant				Copy Number	PDGFRB	Amplification				0.0	0.0																					0				PDGFRB Amplification		MEL-IPI_Pat132	MEL-IPI_Pat132-Tumor-SM-5VWJA	
Biologically Relevant				Mutational Signature	COSMIC Signature 11	version 2	0.981																									0				COSMIC Signature (version 2) 11 (98%)		MEL-IPI_Pat132		
